Thanks for your thoughts Mason. There definitely seems to be...

Thanks for your thoughts Mason. There definitely seems to be plenty of benefits if an oral FTO reformulation can be developed. It makes sense to have this option available and would be a value add with negotiations with any Pharma. Also, IP of this process of development with be invaluable for new molecule in m6a RNA space.

Good question from ma420, providing the return on investment is greater than $3m proposed to be spent then all for it. Whilst I understand that oral formulations are generally more costly the trade-off is enhanced patient comfort and reduced risk of infection of central IV. Raises further question as to whether Zantrene for each indication (AML, ccRCC, Breast cancer and dose deliver type would have their own pricing models)?

When I get time will crunch some number based on the proposed revenue targets for each indication and see if the cost of Zantrene is similar for each.